国家药品监督管理局发文:板蓝根泡腾片等18种药品由处方药转换为非处方药

2018-05-09 佚名 中国中医

5月8日,国家药品监督管理局发布《关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)》。根据《处方药与非处方药分类管理办法(试行)》(国家药品监督管理局令第10号)的规定,经国家药品监督管理局组织论证和审定,板蓝根泡腾片等18种药品由处方药转换为非处方药;伤湿止痛膏已不符合目前乙类非处方药确定原则,由乙类非处方药转换为甲类非处方药。

5月8日,国家药品监督管理局发布《关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)》。根据《处方药与非处方药分类管理办法(试行)》(国家药品监督管理局令第10号)的规定,经国家药品监督管理局组织论证和审定,板蓝根泡腾片等18种药品由处方药转换为非处方药;伤湿止痛膏已不符合目前乙类非处方药确定原则,由乙类非处方药转换为甲类非处方药。

关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)

根据《处方药与非处方药分类管理办法(试行)》(国家药品监督管理局令第10号)的规定,经国家药品监督管理局组织论证和审定,板蓝根泡腾片等18种药品由处方药转换为非处方药;伤湿止痛膏已不符合目前乙类非处方药确定原则,由乙类非处方药转换为甲类非处方药。具体品种名单(附件1)及非处方药说明书范本一并发布(附件2)。

请相关企业在2018年7月6日前,依据《药品注册管理办法》等有关规定提出修订药品说明书的补充申请报药品监督管理部门备案,并将说明书修订的内容及时通知相关医疗机构、药品经营企业等单位。

非处方药说明书范本规定内容之外的说明书其他内容按原批准证明文件执行。药品标签涉及相关内容的,应当一并修订。自补充申请备案之日起生产的药品,不得继续使用原药品说明书。双跨品种的处方药说明书可继续使用。

1板蓝根泡腾片

每片重3.5克

乙类

双跨*

2丹芎瘢痕涂膜

每支装40克

甲类

3儿宝颗粒
(1)每袋装4.5克(低蔗糖型)

(2)每袋装9克(低蔗糖型)

甲类

4复方瓜子金颗粒

每袋装7克(相当于饮片14克)

甲类

5复方黄藤洗液

每瓶装150毫升

甲类

6复方罗汉果清肺糖浆

每瓶装(1)100毫升(2)150毫升

甲类

7葛根汤颗粒

每袋装6克

甲类

8金莲清热胶囊

每粒装0.4克

甲类

9麦味地黄胶囊

每粒重0.35克

甲类

双跨*

10牛黄蛇胆川贝滴丸

每丸重35毫克

乙类

11蒲地蓝消炎片

(1)薄膜衣片每片重0.35克

(2)糖衣片片芯重0.34克

甲类

双跨*

12清火栀麦丸

每袋装0.8克

甲类

13舒肝和胃丸

每袋装6克

甲类

14硫酸氨基葡萄糖胶囊

0.25克(以硫酸氨基葡萄糖计)

甲类

15羟丙甲纤维素滴眼液

0.5%

甲类

16盐酸阿莫罗芬乳膏

0.25%

甲类

17盐酸布替萘芬喷雾剂

10毫升:0.1克

甲类

18右旋糖酐铁分散片

25毫克(按铁计)

甲类

19伤湿止痛膏

甲类

说明:

类别:指非处方药的类别。目前国家对非处方药实施分类管理。非处方药分为甲、乙两类。经营处方药、甲类非处方药的药品零售企业应当配备执业药师或者其他依法经资格认定的药学技术人员。经营乙类非处方药的药品销售企业,应当配备经设区的市级食品药品监督管理机构或者省、自治区、直辖市人民政府食品药品监督管理部门直接设置的县级食品药品监督管理机构组织考核合格的业务人员。
* 为之前已有双跨同类品种的情形。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1819207, encodeId=a52d181920eaa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Aug 30 00:49:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642574, encodeId=e97b16425e427, content=<a href='/topic/show?id=d5f1616583b' target=_blank style='color:#2F92EE;'>#板蓝根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61658, encryptionId=d5f1616583b, topicName=板蓝根)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cc122968840, createdName=minhuang75_72521591, createdTime=Mon Mar 11 03:49:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683934, encodeId=6ed81683934dd, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Apr 07 02:49:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531113, encodeId=05631531113cb, content=<a href='/topic/show?id=ec84409667c' target=_blank style='color:#2F92EE;'>#国家药品监督管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40966, encryptionId=ec84409667c, topicName=国家药品监督管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11612213239, createdName=zhangmingxiang, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589653, encodeId=520e1589653af, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313738, encodeId=302c313e38fb, content=了解了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 10 07:50:41 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313598, encodeId=cc7c313598ce, content=5月8日.国家药品监督管理局发布<关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)>.根据<处方药与非处方药分类管理办法(试行)>(国家药品监督管理局令第10号)的规定.经国家药品监督管理局组织论证和审定.板蓝根泡腾片等18种药品由处方药转换为非处方药,伤湿止痛膏已不符合目前乙类非处方药确定原则.由乙类非处方药转换为甲类非处方药., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Wed May 09 22:52:38 CST 2018, time=2018-05-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1819207, encodeId=a52d181920eaa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Aug 30 00:49:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642574, encodeId=e97b16425e427, content=<a href='/topic/show?id=d5f1616583b' target=_blank style='color:#2F92EE;'>#板蓝根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61658, encryptionId=d5f1616583b, topicName=板蓝根)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cc122968840, createdName=minhuang75_72521591, createdTime=Mon Mar 11 03:49:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683934, encodeId=6ed81683934dd, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Apr 07 02:49:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531113, encodeId=05631531113cb, content=<a href='/topic/show?id=ec84409667c' target=_blank style='color:#2F92EE;'>#国家药品监督管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40966, encryptionId=ec84409667c, topicName=国家药品监督管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11612213239, createdName=zhangmingxiang, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589653, encodeId=520e1589653af, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313738, encodeId=302c313e38fb, content=了解了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 10 07:50:41 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313598, encodeId=cc7c313598ce, content=5月8日.国家药品监督管理局发布<关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)>.根据<处方药与非处方药分类管理办法(试行)>(国家药品监督管理局令第10号)的规定.经国家药品监督管理局组织论证和审定.板蓝根泡腾片等18种药品由处方药转换为非处方药,伤湿止痛膏已不符合目前乙类非处方药确定原则.由乙类非处方药转换为甲类非处方药., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Wed May 09 22:52:38 CST 2018, time=2018-05-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1819207, encodeId=a52d181920eaa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Aug 30 00:49:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642574, encodeId=e97b16425e427, content=<a href='/topic/show?id=d5f1616583b' target=_blank style='color:#2F92EE;'>#板蓝根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61658, encryptionId=d5f1616583b, topicName=板蓝根)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cc122968840, createdName=minhuang75_72521591, createdTime=Mon Mar 11 03:49:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683934, encodeId=6ed81683934dd, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Apr 07 02:49:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531113, encodeId=05631531113cb, content=<a href='/topic/show?id=ec84409667c' target=_blank style='color:#2F92EE;'>#国家药品监督管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40966, encryptionId=ec84409667c, topicName=国家药品监督管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11612213239, createdName=zhangmingxiang, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589653, encodeId=520e1589653af, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313738, encodeId=302c313e38fb, content=了解了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 10 07:50:41 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313598, encodeId=cc7c313598ce, content=5月8日.国家药品监督管理局发布<关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)>.根据<处方药与非处方药分类管理办法(试行)>(国家药品监督管理局令第10号)的规定.经国家药品监督管理局组织论证和审定.板蓝根泡腾片等18种药品由处方药转换为非处方药,伤湿止痛膏已不符合目前乙类非处方药确定原则.由乙类非处方药转换为甲类非处方药., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Wed May 09 22:52:38 CST 2018, time=2018-05-09, status=1, ipAttribution=)]
    2019-04-07 zxl738
  4. [GetPortalCommentsPageByObjectIdResponse(id=1819207, encodeId=a52d181920eaa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Aug 30 00:49:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642574, encodeId=e97b16425e427, content=<a href='/topic/show?id=d5f1616583b' target=_blank style='color:#2F92EE;'>#板蓝根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61658, encryptionId=d5f1616583b, topicName=板蓝根)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cc122968840, createdName=minhuang75_72521591, createdTime=Mon Mar 11 03:49:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683934, encodeId=6ed81683934dd, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Apr 07 02:49:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531113, encodeId=05631531113cb, content=<a href='/topic/show?id=ec84409667c' target=_blank style='color:#2F92EE;'>#国家药品监督管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40966, encryptionId=ec84409667c, topicName=国家药品监督管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11612213239, createdName=zhangmingxiang, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589653, encodeId=520e1589653af, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313738, encodeId=302c313e38fb, content=了解了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 10 07:50:41 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313598, encodeId=cc7c313598ce, content=5月8日.国家药品监督管理局发布<关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)>.根据<处方药与非处方药分类管理办法(试行)>(国家药品监督管理局令第10号)的规定.经国家药品监督管理局组织论证和审定.板蓝根泡腾片等18种药品由处方药转换为非处方药,伤湿止痛膏已不符合目前乙类非处方药确定原则.由乙类非处方药转换为甲类非处方药., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Wed May 09 22:52:38 CST 2018, time=2018-05-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1819207, encodeId=a52d181920eaa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Aug 30 00:49:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642574, encodeId=e97b16425e427, content=<a href='/topic/show?id=d5f1616583b' target=_blank style='color:#2F92EE;'>#板蓝根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61658, encryptionId=d5f1616583b, topicName=板蓝根)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cc122968840, createdName=minhuang75_72521591, createdTime=Mon Mar 11 03:49:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683934, encodeId=6ed81683934dd, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Apr 07 02:49:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531113, encodeId=05631531113cb, content=<a href='/topic/show?id=ec84409667c' target=_blank style='color:#2F92EE;'>#国家药品监督管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40966, encryptionId=ec84409667c, topicName=国家药品监督管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11612213239, createdName=zhangmingxiang, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589653, encodeId=520e1589653af, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313738, encodeId=302c313e38fb, content=了解了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 10 07:50:41 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313598, encodeId=cc7c313598ce, content=5月8日.国家药品监督管理局发布<关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)>.根据<处方药与非处方药分类管理办法(试行)>(国家药品监督管理局令第10号)的规定.经国家药品监督管理局组织论证和审定.板蓝根泡腾片等18种药品由处方药转换为非处方药,伤湿止痛膏已不符合目前乙类非处方药确定原则.由乙类非处方药转换为甲类非处方药., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Wed May 09 22:52:38 CST 2018, time=2018-05-09, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1819207, encodeId=a52d181920eaa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Aug 30 00:49:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642574, encodeId=e97b16425e427, content=<a href='/topic/show?id=d5f1616583b' target=_blank style='color:#2F92EE;'>#板蓝根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61658, encryptionId=d5f1616583b, topicName=板蓝根)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cc122968840, createdName=minhuang75_72521591, createdTime=Mon Mar 11 03:49:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683934, encodeId=6ed81683934dd, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Apr 07 02:49:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531113, encodeId=05631531113cb, content=<a href='/topic/show?id=ec84409667c' target=_blank style='color:#2F92EE;'>#国家药品监督管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40966, encryptionId=ec84409667c, topicName=国家药品监督管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11612213239, createdName=zhangmingxiang, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589653, encodeId=520e1589653af, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313738, encodeId=302c313e38fb, content=了解了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 10 07:50:41 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313598, encodeId=cc7c313598ce, content=5月8日.国家药品监督管理局发布<关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)>.根据<处方药与非处方药分类管理办法(试行)>(国家药品监督管理局令第10号)的规定.经国家药品监督管理局组织论证和审定.板蓝根泡腾片等18种药品由处方药转换为非处方药,伤湿止痛膏已不符合目前乙类非处方药确定原则.由乙类非处方药转换为甲类非处方药., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Wed May 09 22:52:38 CST 2018, time=2018-05-09, status=1, ipAttribution=)]
    2018-05-10 kafei

    了解了谢谢

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1819207, encodeId=a52d181920eaa, content=<a href='/topic/show?id=0805993615a' target=_blank style='color:#2F92EE;'>#非处方#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99361, encryptionId=0805993615a, topicName=非处方)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f98e185, createdName=psybestwish, createdTime=Thu Aug 30 00:49:00 CST 2018, time=2018-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1642574, encodeId=e97b16425e427, content=<a href='/topic/show?id=d5f1616583b' target=_blank style='color:#2F92EE;'>#板蓝根#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61658, encryptionId=d5f1616583b, topicName=板蓝根)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7cc122968840, createdName=minhuang75_72521591, createdTime=Mon Mar 11 03:49:00 CST 2019, time=2019-03-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1683934, encodeId=6ed81683934dd, content=<a href='/topic/show?id=d5d7e23317c' target=_blank style='color:#2F92EE;'>#监督#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72331, encryptionId=d5d7e23317c, topicName=监督)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c95628016941, createdName=zxl738, createdTime=Sun Apr 07 02:49:00 CST 2019, time=2019-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531113, encodeId=05631531113cb, content=<a href='/topic/show?id=ec84409667c' target=_blank style='color:#2F92EE;'>#国家药品监督管理局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40966, encryptionId=ec84409667c, topicName=国家药品监督管理局)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c11612213239, createdName=zhangmingxiang, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589653, encodeId=520e1589653af, content=<a href='/topic/show?id=10f299362a1' target=_blank style='color:#2F92EE;'>#非处方药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99362, encryptionId=10f299362a1, topicName=非处方药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=716117772264, createdName=gracezdd, createdTime=Fri May 11 12:49:00 CST 2018, time=2018-05-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313738, encodeId=302c313e38fb, content=了解了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Thu May 10 07:50:41 CST 2018, time=2018-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=313598, encodeId=cc7c313598ce, content=5月8日.国家药品监督管理局发布<关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)>.根据<处方药与非处方药分类管理办法(试行)>(国家药品监督管理局令第10号)的规定.经国家药品监督管理局组织论证和审定.板蓝根泡腾片等18种药品由处方药转换为非处方药,伤湿止痛膏已不符合目前乙类非处方药确定原则.由乙类非处方药转换为甲类非处方药., beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Wed May 09 22:52:38 CST 2018, time=2018-05-09, status=1, ipAttribution=)]
    2018-05-09 有备才能无患

    5月8日.国家药品监督管理局发布<关于调整板蓝根泡腾片等19个品种管理类别的公告(2018年第16号)>.根据<处方药与非处方药分类管理办法(试行)>(国家药品监督管理局令第10号)的规定.经国家药品监督管理局组织论证和审定.板蓝根泡腾片等18种药品由处方药转换为非处方药,伤湿止痛膏已不符合目前乙类非处方药确定原则.由乙类非处方药转换为甲类非处方药.

    0

相关资讯

国家药品监督管理局发布《省级中药饮片炮制规范修订的技术指导原则》

中药饮片炮制具有悠久的历史,是中医药宝库中的重要组成部分,是我国独特的传统制药技术。饮片炮制是在中医药理论指导下,按中医辨证用药的原则及调剂、制剂的需要,将中药材炮制成饮片的方法和技术。饮片炮制方法规范与否,直接关系到药品质量和临床用药的安全有效,关系到中医药的继承与发展。省级饮片炮制规范是对国家药品标准中未收载的地方临床习用饮片品规和炮制方法的补充,是地方饮片加工、生产、经营、使用、检验、监

国家食药监管总局划定2017年6项药品监管重点工作!

日前,全国药品监管工作会议在京召开。会议认真贯彻落实全国食品药品监督管理工作和表彰先进会议暨党风廉政建设工作会议精神,全面总结2016年药品监管工作情况,部署了2017年重点工作。国家食品药品监督管理总局副局长吴浈出席会议并讲话。会议指出,一年来,全国药品监管战线扎实推进药品监管工作,取得了显著成效。坚持问题导向,严厉整治突出问题,部署开展药品流通、生产领域违法经营行为专项整治,使生产经营秩序进一

药监局将36种药品转换为非处方药品

  根据经国家食品药品监督管理局网站近日消息,国家食品药品监督管理局将安尔眠胶囊等36种药品(化学药品9种,中成药27种)转换为非处方药,并发布了转换的36种药品名单(下表)及其非处方药说明书范本(附件)。国家食品药品监督管理局还要求相关部门进行以上品种说明书和标签的变更工作。   下载附件:安尔眠胶囊等36种非处方药说明书范本 转换为非处方药的36种药品名单